NK-1 Drug Fills Motion Sickness Gap - Poll - MDSpire

NK-1 Drug Fills Motion Sickness Gap

Tradipitant demonstrates 50% to 70% risk reduction for vomiting incidence during motion exposure in phase 3 trials.

  • By

  • Kerri Miller

  • January 2, 2026

  • 3 min

Share

Original Source(s)

NK-1 Drug Fills Motion Sickness Gap

  • by Kerri Miller

  • January 2, 2026

Related Content

Side Effects: Progress, with Asterisks

Burnout is easing. Sleep science is getting weird. And dental schools have been winging cadaver training for 50 years. This week's research is full of good news that immediately complicates itself.

AAE Revises Dental Trauma Guidance

Recommendations outline splinting, replantation timing, imaging, and long-term surveillance strategies for permanent tooth injuries.

Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial